{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:28:17Z","timestamp":1787506097649,"version":"build-2736575974"},"reference-count":44,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the impact of increased federal restrictions on hydrocodone combination product (HCP) utilization, misuse, abuse, and overdose death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed utilization, misuse, abuse, and overdose death trends involving hydrocodone versus select opioid analgesics (OAs) and heroin using descriptive and interrupted time\u2010series (ITS) analyses during the nine quarters before and after the October 2014 rescheduling of HCPs from a less restrictive (CIII) to more restrictive (CII) category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hydrocodone dispensing declined &gt;30% over the study period, and declines accelerated after rescheduling. ITS analyses showed that immediately postrescheduling, quarterly hydrocodone dispensing decreased by 177M dosage units while codeine, oxycodone, and morphine dispensing increased by 49M, 62M, and 4M dosage units, respectively. Postrescheduling, hydrocodone\u2010involved misuse\/abuse poison center (PC) case rates had a statistically significant immediate drop but a deceleration of preperiod declines. There were small level increases in codeine\u2010involved PC misuse\/abuse and overdose death rates immediately after HCP's rescheduling, but these were smaller than level decreases in rates for hydrocodone. Heroin\u2010involved PC case rates and overdose death rates increased across the study period, with exponential increases in PC case rates beginning 2015.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HCP rescheduling was associated with accelerated declines in hydrocodone dispensing, only partially offset by smaller increases in codeine, oxycodone, and morphine dispensing. The net impact on hydrocodone and other OA\u2010involved misuse\/abuse and fatal overdose was unclear. We did not detect an immediate impact on heroin abuse or overdose death rates; however, the dynamic nature of the crisis and data limitations present challenges to causal inference.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.5603","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T03:35:27Z","timestamp":1676259327000},"page":"735-751","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths"],"prefix":"10.1002","volume":"32","author":[{"given":"Sara","family":"Karami","sequence":"first","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebola","family":"Ajao","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamra","family":"Meyer","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Ding","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-1631","authenticated-orcid":false,"given":"Alex","family":"Secora","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"},{"name":"Associate Director Epidemiology, IQVIA Government Solutions  Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Major","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajdeep","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace P.","family":"Chai","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"McAninch","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II (DEPI\u2010II) Office of Pharmacovigilance and Epidemiology(OPE), Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)  Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"American Addiction Centers.Hydrocodone (Vicodin Norco) addiction and treatment. February 3 2020. Accessed November 1 2020.https:\/\/americanaddictioncenters.org\/hydrocodone-treatment\/#Hydrocodone."},{"key":"e_1_2_12_3_1","unstructured":"American Addiction Centers.Hydrocodone addiction: symptoms and signs of abuse. February 3 2020. Accessed November 1 2020.https:\/\/americanaddictioncenters.org\/hydrocodone-treatment\/signs-of-abuse\/."},{"key":"e_1_2_12_4_1","unstructured":"Edwards J.One nation on Vicodin: narcotic painkillers are most\u2010used U.S. drugs. CBS Interactive Inc. Money Watch. April 20 2011. Accessed November 1 2020.https:\/\/www.cbsnews.com\/news\/one-nation-on-vicodin-narcotic-painkillers-are-most-used-us-drugs\/"},{"key":"e_1_2_12_5_1","unstructured":"IMS Institute for Healthcare Informatics.Medicines use and spending in the U.S. A review of 2015 and Outlook to 2020. April 2016. Accessed November 1 2020.https:\/\/morningconsultcom\/wp-content\/uploads\/2016\/04\/IMS-Institute-US-Drug-Spending-2015pdf."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.2146\/news130017"},{"key":"e_1_2_12_7_1","unstructured":"U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality.Short report. Emergency department visits involving narcotic pain relievers. November 5 2015. Accessed November 1 2020.https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/report_2083\/ShortReport-2083.html."},{"key":"e_1_2_12_8_1","unstructured":"American Medical Association.DEA final rule rescheduling hydrocodone combination production. Accessed November 1 2020.https:\/\/www.entnet.org\/sites\/default\/files\/AMA_FactSheet_hydrocodone.pdf."},{"key":"e_1_2_12_9_1","first-page":"1","article-title":"Trends in opioids prescribed at discharge from emergency departments among adults: United States, 2006\u20102017","volume":"135","author":"Rui P","year":"2020","journal-title":"Natl Health Stat Report"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnz210"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2020.09.013"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2022.2063898"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_12_14_1","unstructured":"RADARS\u00ae System.What Is the RADARS system? 2020. Accessed November 1 2020.https:\/\/www.radars.org\/."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.02.003"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2016.1245421"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2019.1677022"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2018.1533727"},{"key":"e_1_2_12_19_1","unstructured":"Micromedex\u00ae Solutions Tox & Drug OProduct Lookup.2017 Truven Health Analytics LLC. Accessed November 1 2020.http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian."},{"key":"e_1_2_12_20_1","first-page":"1","article-title":"Using literal text from the death certificate to enhance mortality statistics: characterizing drug involvement in deaths","volume":"65","author":"Trinidad JP","year":"2016","journal-title":"Natl Vital Stat Rep"},{"issue":"10","key":"e_1_2_12_21_1","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2010\u20102014","volume":"65","author":"Warner M","year":"2016","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_2_12_22_1","unstructured":"AhmadFB CisewskiJA RossenLM SuttonP.Provisional drug overdose death counts.National Center for Health Statistics. 2022. Accessed October 14 2022.https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"key":"e_1_2_12_23_1","volume-title":"SAS\/STAT\u00ae User's Guide, Version 8. Chapter 3: Introduction to Regression Procedures","author":"SAS Institute Inc.","year":"1999"},{"key":"e_1_2_12_24_1","unstructured":"CDC WONDER.Bridged\u2010race population estimates 1990\u20102015 request. Accessed November 1 2020.https:\/\/wondercdcgov\/Bridged-Race-v2016HTML."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01235-8"},{"key":"e_1_2_12_27_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019"},{"key":"e_1_2_12_28_1","unstructured":"Drug Enforcement Administration.Diversion control division drug & chemical evaluation section.TramadolMarch 2020. Accessed June 30 2021.https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/tramadol.pdf."},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.7799"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1765"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2017.01.010"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2016.08.026"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.024901"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2017.03.057"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027117"},{"issue":"10","key":"e_1_2_12_36_1","first-page":"449","article-title":"Impact of the hydrocodone schedule change on opioid prescription patterns in South Dakota","volume":"70","author":"Kuschel LM","year":"2017","journal-title":"SD Med"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaa157"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4869"},{"key":"e_1_2_12_39_1","unstructured":"National Drug Early Warning System.Webinar. Recent enhancements in the timeliness and specificity of drug overdose death certificate data from NCHS by Margaret Warner. May 22 2019. Accessed March 25 2021.https:\/\/ndews.org\/publications\/webinars-2\/."},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyy135"},{"key":"e_1_2_12_41_1","unstructured":"VA\/DoD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain.U.S. Department of Veterans Affairs. 2003. Accessed June 10 2021.https:\/\/www.va.gov\/painmanagement\/docs\/chronicpainguidelinesva2003.pdf."},{"key":"e_1_2_12_42_1","unstructured":"VA\/DoD Clincial Practice Guideline for Management of Opioid Therapy for Chronic Pain.U.S. Department of Veterans Affairs. 2010. Accessed June 10 2021.https:\/\/www.va.gov\/painmanagement\/docs\/cpg_opioidtherapy_fulltext.pdf"},{"key":"e_1_2_12_43_1","unstructured":"United States Food and Drug Administration.FDA Briefing Document. Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). May 2016. Accessed June 10 2021.https:\/\/www.fda.gov\/media\/96897\/download"},{"key":"e_1_2_12_44_1","unstructured":"Washington State Agency Medical Directors' Group (AMDG) in collaboration with an Expert Advisory Panel Actively Practicing Providers Public Stakeholders and Senior State Officials. Interagency Guideline on Prescribing Opioids for Pain Developed. 3rd Edition. June 2015. Accessed June 10 2021.http:\/\/www.agencymeddirectors.wa.gov\/Files\/2015AMDGOpioidGuideline.pdf"},{"key":"e_1_2_12_45_1","volume-title":"Common Elements in Guidelines for Prescribing Opioids for Chronic Pain","author":"Centers for Disease Prevention and Control","year":"2015"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5603","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T10:26:37Z","timestamp":1692440797000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/pds.5603"],"URL":"https:\/\/doi.org\/10.1002\/pds.5603","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"2022-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}